Illumina (NASDAQ:ILMN) Sees Large Volume Increase

Illumina, Inc. (NASDAQ:ILMN) shares saw unusually-strong trading volume on Friday . Approximately 3,842,891 shares changed hands during trading, an increase of 146% from the previous session’s volume of 1,562,757 shares.The stock last traded at $94.06 and had previously closed at $95.20.

Analyst Ratings Changes

A number of equities research analysts have commented on ILMN shares. Sanford C. Bernstein initiated coverage on shares of Illumina in a research report on Thursday, September 28th. They issued an “underperform” rating and a $111.00 price objective on the stock. Stifel Nicolaus restated a “buy” rating and set a $200.00 target price on shares of Illumina in a research note on Thursday, October 12th. Barclays dropped their price target on shares of Illumina from $150.00 to $100.00 and set an “underweight” rating on the stock in a research note on Friday, September 29th. Bank of America reduced their price objective on shares of Illumina from $230.00 to $210.00 in a research report on Thursday, August 10th. Finally, Evercore ISI reiterated an “outperform” rating and set a $240.00 price target on shares of Illumina in a research note on Friday, September 1st. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $194.56.

Illumina Trading Down 0.7 %

The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.28 and a current ratio of 1.69. The stock has a market capitalization of $15.01 billion, a PE ratio of -13.20, a price-to-earnings-growth ratio of 6.66 and a beta of 1.16. The business’s 50-day moving average is $126.06 and its two-hundred day moving average is $167.17.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, November 9th. The life sciences company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.20. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a negative net margin of 25.20% and a positive return on equity of 2.13%. The business’s revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.34 earnings per share. As a group, equities research analysts anticipate that Illumina, Inc. will post 0.68 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $167.04, for a total value of $83,520.00. Following the completion of the transaction, the senior vice president now owns 45,524 shares in the company, valued at $7,604,328.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Illumina news, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $167.04, for a total transaction of $83,520.00. Following the transaction, the senior vice president now directly owns 45,524 shares in the company, valued at $7,604,328.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Aimee L. Hoyt sold 315 shares of the stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $112.84, for a total transaction of $35,544.60. Following the completion of the transaction, the senior vice president now directly owns 8,314 shares of the company’s stock, valued at $938,151.76. The disclosure for this sale can be found here. Company insiders own 0.13% of the company’s stock.

Institutional Trading of Illumina

Several large investors have recently bought and sold shares of the company. Polen Capital Management LLC boosted its position in shares of Illumina by 0.6% in the 3rd quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company’s stock worth $703,782,000 after buying an additional 29,153 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in shares of Illumina by 5.5% in the third quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company’s stock valued at $550,212,000 after purchasing an additional 208,267 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Illumina by 6.6% in the third quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company’s stock valued at $500,926,000 after purchasing an additional 225,074 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Illumina by 18.6% in the second quarter. Geode Capital Management LLC now owns 3,473,112 shares of the life sciences company’s stock valued at $649,525,000 after purchasing an additional 544,786 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Illumina by 268.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,113,230 shares of the life sciences company’s stock worth $427,295,000 after purchasing an additional 1,539,186 shares in the last quarter. Institutional investors and hedge funds own 92.17% of the company’s stock.

About Illumina

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.